1.    PRODUCT OVERVIEW

1.1.  MARKET DEFINITION

1.2.  SCOPE OF THE MARKET

1.2.1.    MARKETS COVERED

1.2.2.    YEARS CONSIDERED FOR STUDY

1.2.3.    KEY MARKET SEGMENTATIONS

2.    RESEARCH METHODOLOGY

2.1.  OBJECTIVE OF THE STUDY

2.2.  BASELINE METHODOLOGY

2.3.  KEY INDUSTRY PARTNERS

2.4.  MAJOR ASSOCIATION AND SECONDARY SOURCES

2.5.  FORECASTING METHODOLOGY

2.6.  DATA TRIANGULATION & VALIDATION

2.7.  ASSUMPTIONS AND LIMITATIONS

3.    EXECUTIVE SUMMARY

3.1.  OVERVIEW OF THE MARKET

3.2.  OVERVIEW OF KEY MARKET SEGMENTATIONS

3.3.  OVERVIEW OF KEY MARKET PLAYERS

3.4.  OVERVIEW OF KEY REGIONS/COUNTRIES

3.5.  OVERVIEW OF MARKET DRIVERS, CHALLENGES, TRENDS

4.    VOICE OF CUSTOMER

5.     JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET OUTLOOK

5.1.  MARKET SIZE & FORECAST

5.1.1.    BY VALUE

5.2.  MARKET SHARE & FORECAST

5.2.1.    BY DRUG (BIOLOGICS, NON-BIOLOGICS)

5.2.2.    BY DRUG CLASS (ANTIDEPRESSANTS, ANALGESICS, IMMUNOMODULATORS, INTERFERONS, DECARBOXYLASE INHIBITORS, OTHERS)

5.2.3.    BY DISEASE (NEUROVASCULAR DISEASE, NEURODEGENERATIVE DISEASES, DEGENERATIVE DISEASE, INFECTIOUS DISEASE, MENTAL HEALTH, CNS CANCER, OTHERS)

5.2.4.    BY DISTRIBUTION CHANNEL (HOSPITAL-BASED PHARMACIES, RETAIL PHARMACIES, ONLINE PHARMACIES)

5.2.5.    BY REGION

5.2.6.    BY COMPANY (2024)

5.3.  MARKET MAP

6.    HOKKAIDO CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET OUTLOOK

6.1.  MARKET SIZE & FORECAST

6.1.1.    BY VALUE

6.2.  MARKET SHARE & FORECAST

6.2.1.    BY DISEASE TYPE

7.    TOHOKU CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET OUTLOOK

7.1.  MARKET SIZE & FORECAST

7.1.1.    BY VALUE

7.2.  MARKET SHARE & FORECAST

7.2.1.    BY DISEASE TYPE

8.    KANTO CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET OUTLOOK

8.1.  MARKET SIZE & FORECAST

8.1.1.    BY VALUE

8.2.  MARKET SHARE & FORECAST

8.2.1.    BY DISEASE TYPE    

9.    CHUBU CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET OUTLOOK

9.1.  MARKET SIZE & FORECAST

9.1.1.    BY VALUE

9.2.  MARKET SHARE & FORECAST

9.2.1.    BY DISEASE TYPE

10. KANSAI CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET OUTLOOK

10.1.   MARKET SIZE & FORECAST        

10.1.1. BY VALUE

10.2.   MARKET SHARE & FORECAST

10.2.1. BY DISEASE TYPE

11. CHUGOKU CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET OUTLOOK

11.1.   MARKET SIZE & FORECAST        

11.1.1. BY VALUE

11.2.   MARKET SHARE & FORECAST

11.2.1. BY DISEASE TYPE

12. SHIKOKU CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET OUTLOOK

12.1.   MARKET SIZE & FORECAST        

12.1.1. BY VALUE

12.2.   MARKET SHARE & FORECAST

12.2.1. BY DISEASE TYPE

13. KYUSHU CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET OUTLOOK

13.1.   MARKET SIZE & FORECAST        

13.1.1. BY VALUE

13.2.   MARKET SHARE & FORECAST

13.2.1. BY DISEASE TYPE

14. MARKET DYNAMICS

14.1.   DRIVERS

14.2.   CHALLENGES

15. MARKET TRENDS & DEVELOPMENTS

15.1.   RECENT DEVELOPMENTS

15.2.   PRODUCT LAUNCHES

15.3.   MERGERS & ACQUISITIONS

16.  JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET: SWOT ANALYSIS

17. COMPETITIVE LANDSCAPE

17.1.   ABBVIE INC.

17.1.1.       BUSINESS OVERVIEW

17.1.2.       PRODUCT & SERVICE OFFERINGS

17.1.3.       RECENT DEVELOPMENTS

17.1.4.       FINANCIALS (IF LISTED)

17.1.5.       KEY PERSONNEL

17.1.6.       SWOT ANALYSIS

17.2.   ASTRAZENECA

17.3.   OTSUKA PHARMACEUTICAL CO., LTD.

17.4.   BRISTOL MYERS SQUIBB COMPANY

17.5.   ELI LILLY AND COMPANY

17.6.   JOHNSON & JOHNSON SERVICES, INC.

17.7.   EISAI CO., LTD.

17.8.   ASTELLAS PHARMA INC.

17.9.   SHIONOGI & CO., LTD

17.10. MERCK & CO., INC

18. STRATEGIC RECOMMENDATIONS

19. ABOUT US & DISCLAIME